Labiotech.eu

In Depth 22 Jul 2022

The coming of age story of RNAi technology

The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […]

July 22, 2022 - 7 minutesmins - By Farhan Mitha

News and Trends 22 Jul 2022

Australia looks to biotech alliance

The Australian government’s Defence department has announced the launch of the Safeguarding Australia through Biotechnology Response and Engagement alliance (SABRE) at the inaugural Australian Defence Science Technology and Research Summit (ADSTAR) The department said SABRE offers opportunities by bringing together different perspectives of biotech from Australia’s universities, research institutes and small medium enterprises (SME) and […]

July 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Jul 2022

Astellas to create new biotech campus in South San Francisco

Astellas Pharma Inc. has unveiled plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The new 154,000-square-foot building at 480 Forbes Boulevard will allow for the co-location of several Astellas business units and functions currently located independently throughout the San Francisco area. The new innovation […]

July 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Jul 2022

Stroke drug given priority medicine status by European Medicines Agency

A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […]

July 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […]

July 22, 2022

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 22 Jul 2022

Consortium awarded €4M towards platform for personalized cell therapies

A company developing precision T cell therapies that treat solid tumors announced yesterday (July 21) it is leading a consortium that has been awarded a €4 million ($4.2 million) grant from Horizon Europe. The new consortium is being led by Achilles Therapeutics plc and includes CGT Catapult, Leibniz University Hannover (Hannover) as project coordinator, and […]

July 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

Poolbeg Pharma gets approval for severe influenza drug trial

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza. Clinical trial activities will formally commence on […]

July 21, 2022 - 4 minutesmins - By Jim Cornall

Interview 21 Jul 2022

Finding investment opportunities in a bleak biotech stock market

The situation remains difficult in public markets as biotech stocks struggle to recover from a 50% decline over the past year. However, the venture capital (VC) firm Sofinnova Partners is no stranger to downturns, and partner Joe Anderson explains how the industry is shifting in favor of life sciences investors. It’s a tough time to […]

July 21, 2022 - 7 minutesmins - By Jonathan Smith

coronavirus COVID 19 Europe biotech lungs

News and Trends 21 Jul 2022

Additional funding for trial to study drug targeting lung immunity in elderly patients

Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead from Health Canada. Qu Biologics will receive additional funding to launch the trial for the restoration of innate immune function – the defense system humans are born with. Qu, a private clinical stage biopharmaceuticals company […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

Almirall launches new call to find innovative therapies for skin diseases

A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company

U.S. biopharma company ZyVersa Therapeutics, Inc., and Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, have entered into a definitive business combination agreement. The transaction is expected to provide ZyVersa with access to the public equity market, which the parties believe will escalate development of ZyVersa’s renal and inflammasome product candidate pipelines. Upon […]

July 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Jul 2022

Eiger receives European approval for progeria treatment

Eiger BioPharmaceuticals Inc., which focuses on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, has received marketing authorization from the European Commission (EC) for Zokinvy (lonafarnib), a therapy for children and young adults with Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL). Collectively known as progeria, […]

July 21, 2022 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The coming of age story of RNAi technology

Australia looks to biotech alliance

Astellas to create new biotech campus in South San Francisco

Stroke drug given priority medicine status by European Medicines Agency

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

Consortium awarded €4M towards platform for personalized cell therapies

Poolbeg Pharma gets approval for severe influenza drug trial

Finding investment opportunities in a bleak biotech stock market

Additional funding for trial to study drug targeting lung immunity in elderly patients

Almirall launches new call to find innovative therapies for skin diseases

ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company

Eiger receives European approval for progeria treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!